United States

Analyst Research Report Snapshot


Medivir AB






17 Dec 2014





Companies referenced:


Available for Immediate Download

Medivir AB - Company Report, is a source of comprehensive company data and information. The report covers the company’s structure, operation, product and service offerings, and corporate actions, providing a 360° view of the company. Features: - Detailed information on Medivir AB required for business and competitor intelligence needs - Intelligence on Medivir AB’s mergers and acquisitions (M&A), strategic partnerships and alliances, capital raising, private equity transactions, and financial and legal advisors - News about Medivir AB, such as business expansion, restructuring, and contract wins - Large number of easy-to-grasp charts and graphs that present important data and key trends Highlights: Medivir is a research-based pharmaceutical company that focuses on the development of treatments for infectious diseases. The company is engaged in polymerase and protease drug targets and drug development. Its key product is simeprevir, a novel protease inhibitor for the treatment of hepatitis C. Medivir provides pharmaceutical products for a range of therapeutic areas which includes cold sores; pain treatment; mental disorder, bipolar disorder; coughing, asthma and chronic obstructive pulmonary disease (COPD) (a disease of the lungs); musculoskeletal system (a collective name given to the skeleton, muscles, tendons and ligaments); gastrointestinal problems, diarrhea, constipation and digestive disorders; cardiovascular diseases; zinc deficiency; and gout diseases. The company primarily operates in Sweden, where it is headquartered in Huddinge and employs around 105 people. The company recorded revenues of SEK555 million (approximately $82 million) in the fiscal year ended December 2012, a decrease of 20.5% compared to 2011. The company's operating loss was SEK185.8 million (approximately $27.5 million) in fiscal 2012, as compared to an operating profit of SEK111.8 million (approximately $16.5 million) in 2011. Its net loss was SEK219.1 million (approximately $32.4 million) in fiscal 2012, as compared to the net profit of SEK113.8 million (approximately $16.8 million) in 2011. Reasons to Purchase: - Gain understanding of Medivir AB the company and its strategies - Track strategic initiatives of the company and latest corporate news and actions - Assess Medivir AB as a prospective partner, vendor or supplier - Support sales activities by understanding your customers' businesses better - Stay up to date on Medivir AB your competitors' business structure, strategy and prospects

Why buy analyst research?

  • Institutional quality research
  • Available for Immediate Download
  • Detailed company or industry insight
  • Print or save
  • 24 hour customer support
Return to previous page without adding this item to your cart.
Email Customer Support.

About Analyst Research

Analyst research reports are available for immediate download after purchase. You will have unlimited access to the report for 24 hours after purchase, to download, print or save it as many times as you wish. Analyst Research provided by Reuters does not constitute investment advice, and is not endorsed by Reuters Research. This information is protected by copyright and intellectual property laws. More information on Analyst Research.